The pharmaceutical industry is aggressively evolving, with increasing demand for high-performance Active Pharmaceutical Ingredients (APIs). Dulaglutide, a GLP-1 receptor agonist, stands as copyrightple of this trend. To fulfill this demand, US-based manufacturing services are emerging. These providers offer a comprehensive suite of services, from r